Revenue growth outpaced costs as operating margin jumps 11.97 percentage points
Consolidated Q2FY27 profit rose 267.85% QoQ; lower interest and a 0.55-point tax-rate reduction added support, while other income was only 0.17% of pre-tax profit.
Filed 05 Nov 2026, 20:02 IST · after market close · Symbiotec Pharmalab Ltd (SYMBIOTEC)
Key takeaways
- Consolidated revenue grew 28.32% QoQ while expenses rose 8.94%, lifting operating profit growth to 102.46%.
- Operating margin expanded 11.97 percentage points to 32.69%, 11.02 percentage points above the 78-peer Healthcare median.
- Net profit rose 267.85% QoQ to Rs 51.72 cr, with other income contributing only 0.17% of pre-tax profit.
Price around the results
Revenue acceleration widened the operating spread
Consolidated revenue grew 28.32% QoQ, well ahead of the 8.94% increase in expenses, so operating profit rose 102.46%. Net profit increased 267.85% QoQ to Rs 51.72 cr. The results were filed after market close on 05 Nov 2026.
Margin expansion came mainly from cost discipline
Operating margin widened 11.97 percentage points to 32.69% because revenue growth outpaced expense growth. Interest expense fell 7.77%, while the tax rate declined 0.55 percentage points to provide additional support to net profit. Other income was only 0.17% of pre-tax profit, so it was not a meaningful driver of earnings.
Q2 margin moved above the Healthcare peer median
The available sequential trend shows operating margin improving from 20.72% in Q1FY27 to 32.69% in Q2FY27. Symbiotec's margin was 11.02 percentage points above the 21.67% median for the 78 Healthcare peers that had reported the quarter.
Management outlined new-business and capacity plans
Management said revenue from new businesses is expected to begin within the next six to twelve months. The presentation said gross capex is estimated at Rs 1,666 cr by the end of FY27, and that the company plans to initiate 600 kilolitres of capacity backed by a customer agreement.
No post-results market move is available yet
The consolidated results were filed after market close. A post-results market move cannot yet be assessed.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹280 cr | ₹218 cr | +28.32% |
| Other income | ₹0 cr | ₹0 cr | -67.65% |
| Expenses | ₹188 cr | ₹173 cr | +8.94% |
| Operating profit | ₹92 cr | ₹45 cr | +102.46% |
| Operating margin (%) | 32.69% | 20.72% | — |
| Interest | ₹6 cr | ₹6 cr | -7.77% |
| Depreciation | ₹22 cr | ₹22 cr | +0.23% |
| Profit before tax | ₹64 cr | ₹18 cr | +265.32% |
| Tax | ₹12 cr | ₹3 cr | +255.33% |
| Net profit | ₹52 cr | ₹14 cr | +267.85% |
| EPS (₹) | ₹8.20 | ₹2.24 | +266.07% |
Operating margin of 32.69% compares with a Healthcare sector median of 21.67% across 78 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Revenue from the new businesses is expected to commence in the next six to twelve months.
Expansion
- Gross capex is estimated at ₹1,666 crore by the end of FY27.
- The company plans to initiate 600 kilolitres of capacity backed by a customer agreement.
What to watch
- Whether operating margin stays above 32.69% after the Q2 expansion.
- Whether new-business revenue begins within the six-to-twelve-month window management cited.
- Progress toward the Rs 1,666 cr FY27 gross-capex estimate and the planned 600-kilolitre capacity.